Recommendations Developed on How to Manage Research Incidental Findings

experts has developed the first major guidelines on managing incidental findings (IFs) in human subjects research.

The two-year project, led by Susan Wolf, J.D., professor and chair of the University of Minnesota's (Indianapolis; USA) Consortium on Law and Values in Health, Environment, and the Life Sciences, and supported by the U.S. National Human Genome Research Institute (NHGRI) at National Institutes of Health (Bethesda, MD, USA), has now issued groundbreaking recommendations for how to anticipate and manage IFs in genetic, genomic, and imaging research, suggesting a broader application to other research domains. The project has produced a 17-article symposium including the consensus paper, which appears in the Summer 2008, issue of the Journal of Law, Medicine & Ethics.

An incidental finding (IF) is an unexpected finding concerning an individual research participant that has potential health or reproductive importance, is discovered in the course of conducting research, but is beyond the aims of the study. They are an increasingly common byproduct of research using powerful technologies that generate extra data. Because IFs can potentially save lives but also cause alarm, the decision on whether or not to disclose them to research participants has been a major dilemma.

"Researchers often stumble upon unexpected findings but have no idea whether to share this information with research participants,” said Dr. Wolf. "The information may prove highly significant or a false alarm. And researchers have traditionally drawn a bright line between their research activity and the clinical care of patients; incidental findings challenge that line.”

The project members concluded that it is necessary to address the possibility of IFs in the consent process. Researchers should initiate a process for recognizing IFs and verifying whether there is indeed a suspicious finding of concern, and they should take steps to validate an IF and confirm its health or reproductive importance before offering the finding to a research participant. Furthermore, a researcher who lacks the expertise to make this assessment may need to consult a clinical colleague. The consensus report also addresses the troublesome problem of IFs discovered in reanalysis of archived data.

The consensus article distinguishes among three categories of IFs to determine when they should be disclosed. IFs with strong net benefits--ones revealing a condition likely to be life-threatening or revealing a condition likely to be grave that can be avoided--should be offered to research participants. An IF that offers possible net advantage--one that may offer more benefit than burden to the research participant--may be disclosed at the researcher's discretion. An IF that has unlikely net benefit or whose net benefit cannot be determined should not be offered to the research participant, because disclosure may well present more burden than benefit.

"These guidelines should have an enormous impact,” Dr. Wolf said. "They should prompt federal authorities, universities, institutional review boards, and researchers to develop strategies for dealing with incidental findings and to discuss the plan with people signing up to participate in research.”

The University of Minnesota's Consortium on Law and Values in Health, Environment, and the Life Sciences was created to address the societal implications of the life sciences and biomedicine.


Related Links:
University of Minnesota
University of Minnesota's Consortium on Law and Values in Health, Environment, and the Life Sciences